NEW YORK, June 5, 2014 /CNW/ - Canaccord Genuity is pleased to announce
the expansion of its Healthcare Equity Research team with the hiring of
Corey Davis, Ph.D., as a Managing Director covering Specialty
Pharmaceuticals, with a focus in certain therapeutics areas within the
"We are pleased to welcome Corey Davis to the Canaccord Genuity
Healthcare team," commented Stephen Buell, Global Head of Equity
Research at Canaccord Genuity Inc. "Corey's versatile experience
enhances Canaccord Genuity's ability to continue to provide clients
with high-quality, independent, global equity research coverage within
the dynamic and opportunity-rich healthcare sector."
Mr. Davis brings over 16 years of sell-side experience covering
Specialty Pharmaceuticals companies, most of those years at JP Morgan
and at Jefferies. He is widely recognized for his expertise on a broad
range of key issues within the industry, including IP law, CNS-related
disorders, clinical trial design, financial modelling, and has deep
relationships with thought leaders in the industry. Mr. Davis earned a
BA in Biology from Middlebury College in 1991 and a Ph.D. in Molecular
Biology at Princeton University in 1997.
At Canaccord Genuity, Corey will establish strong coverage of key
Specialty Pharmaceuticals names, as well as a series of later-stage
biopharmaceutical companies that offer investors a broad range of
investment opportunities in drug development.
Canaccord Genuity's global coverage of the Healthcare sector now
includes eight analysts across three continents, covering
Biotechnology, Specialty Pharmaceuticals, Medical Devices, Medical
Diagnostics, Life Sciences Tools and Healthcare Services. At present,
Canaccord Genuity has nearly 150 equity research professionals globally
and more than 950 companies under coverage.
ABOUT CANACCORD GENUITY:
Canaccord Genuity is the global capital markets division of Canaccord
Genuity Group Inc. (TSX: CF, LSE: CF.), offering institutional and
corporate clients idea-driven investment banking, merger and
acquisition, research, sales and trading services from offices in 11
countries worldwide. Our team of nearly 1,000 capital markets and
advisory professionals has industry and transactional expertise in 18
key sectors of the global economy. We are committed to providing valued
services to our clients throughout the entire lifecycle of their
business and operating as a gold standard independent investment bank -
expansive in resources and reach, but targeted in industry expertise,
market focus and individual client attention.
More information is available at www.canaccordgenuity.com.
ABOUT CANACCORD GENUITY GROUP INC.:
Through its principal subsidiaries, Canaccord Genuity Group Inc. (the
"Company") is a leading independent, full-service financial services
firm, with operations in two principal segments of the securities
industry: wealth management and capital markets. Since its
establishment in 1950, the Company has been driven by an unwavering
commitment to building lasting client relationships. We achieve this by
generating value for our individual, institutional and corporate
clients through comprehensive investment solutions, brokerage services
and investment banking services. The Company has offices in 11
countries worldwide, including Wealth Management offices located in
Canada, Australia, the UK and Europe. Canaccord Genuity, the
international capital markets division, operates in Canada, the U.S.,
the U.K., France, Germany, Ireland, Hong Kong, mainland China,
Singapore, Australia and Barbados. To us there are no foreign markets.™
Canaccord Genuity Group Inc. is publicly traded under the symbol CF on
the TSX and the symbol CF. on the London Stock Exchange.
SOURCE: Canaccord Financial Inc.
For further information: